Atlanta, GA, December 05, 2017 --(PR.com
)-- CardioLync will be presenting in the Seed Stage Track of the prestigious youngStartUp Ventures, 2017 New England Venture Summit in Boston Randolph Dec 6th. With representatives of more than 100 Venture Capital firms confirmed for the conference, CardioLync was selected by youngStartUp Ventures to introduce to the finance community its innovative technology that enables physician-patient social networking for improving care and improving patient outcomes.
Jeremy Kagan, Founder and CEO of CardioLync will be presenting in the morning session, and will be available for one-on-one meetings at the conference later in the day. According to Jeremy Kagan, "I am excited to have the opportunity to present CardioLync's leading edge solution to financiers who are looking to stay ahead of the curve. Medical reimbursement is moving rapidly to outcome-based payments and hospital networks and medical practices large and small have to adapt. Considering that Cardiovascular Disease is the number one cause of death, and 50% of men and 64% of women who die suddenly of heart disease have no previous symptoms, many if not most of these deaths could have been prevented through routine diagnostic tests and follow-up. CardioLync has developed a unique technology that facilitates access to specialist interpreting physicians and engages patients to be more actively involved and reduce readmissions. The feedback that we are getting from physicians is that CardioLync's technology will help them improve patient outcomes as well as their own bottom lines."
CardioLync has developed a Diagnostic Interface Portal that facilitates scheduling, tracking, interpretation and reporting of medical diagnostic studies including imaging; consolidation of outpatient and personal monitoring device data; and Doctor-Patient social networking that turns care into an ongoing participatory team effort to reduce surprises. CardioLync is led by experienced technologists and clinical practitioners looking to solve the needs of ageing populations within the financial constraints of changing medical reimbursement models.